Lanreotide

Patients taking insulin, oral hypoglycaemic drugs, and β-blockers: Dose adjustment may be necessary.

SC
Acromegaly
CrCl <60 mL/minute: Initially, 60 mg via deep SC injection once every 4 weeks for 3 months, adjust dose according to patient’s response, GH and/or IGF-1 levels. Dosing recommendations may vary among countries or individual products or preparations. Refer to country- or product-specific recommendations.

SC
Acromegaly
Moderate to severe (Child-Pugh Class B and C): Initially, 60 mg via deep SC injection once every 4 weeks (28 days) for 3 months, adjust dose according to patient’s response, GH and/or IGF-1 levels. Dosing recommendations may vary among countries or individual products or preparations. Refer to country- or product-specific recommendations.

Patient with pre-existing cardiac disease, biliary disorder (e.g. cholelithiasis), diabetes, thyroid disorder. Moderate to severe renal and hepatic impairment (if used in acromegaly treatment). Pregnancy.

Significant: Cholelithiasis including complications (e.g. cholecystitis, cholangitis, pancreatitis), diarrhoea, abdominal pain, hyperglycaemia or hypoglycaemia, hypersensitivity (e.g. angioedema, anaphylaxis), hypothyroidism, bradycardia, hypertension.
Blood and lymphatic system disorders: Anaemia.
Cardiac disorders: Dyspnoea.
Gastrointestinal disorders: Constipation, flatulence, loose stools, nausea, steatorrhoea, vomiting.
General disorders and admin site conditions: Injection site reaction (e.g. induration, pain, mass, nodule, pruritus, abscess), lethargy.
Hepatobiliary disorders: Biliary dilatation, gallbladder sludge.
Immune system disorders: Antibody development.
Investigations: Weight loss.
Metabolism and nutrition disorders: Diabetes mellitus.
Musculoskeletal and connective tissue disorders: Arthralgia, musculoskeletal pain, muscle spasm, myalgia.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Depression, insomnia.
Skin and subcutaneous tissue disorders: Alopecia.
Vascular disorders: Hot flushes.

Parenteral/SC: C

This drug may cause dizziness, if affected, do not drive or operate machinery.

Monitor serum GH and IGF-1 level, gallstone formation, thyroid function, renal and hepatic function, heart rate, blood pressure, blood glucose.

May increase serum concentration of bromocriptine. May decrease intestinal absorption and bioavailability of ciclosporin. May decrease metabolic clearance of drugs metabolised by CYP3A4 (e.g. terfenadine, quinidine).

Description:
Mechanism of Action: Lanreotide, a synthetic octapeptide analogue of natural somatostatin has high affinity to human somatostatin receptors SSTR 2 and 5 found in pituitary gland and growth hormones secreting neoplasm of pituitary gland which results in the inhibition of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) secretion.
Pharmacokinetics:
Absorption: Absolute bioavailability: Approx 55-80%. Time to peak plasma concentration: 7-12 hours.
Distribution: Volume of distribution: 15.14 L.
Excretion: Via urine (<5% as unchanged drug); faeces (<0.5% as unchanged drug). Terminal elimination half-life: Approx 2.5 hours (IV); approx 5-30 days (SC/IM).

Source: https://pubchem.ncbi.nlm.nih.gov/

Store between 2-8°C. Do not freeze. Protect from light.

Hormon dinh dưỡng & các thuốc tổng hợp có liên quan

H01CB03 - lanreotide ; Belongs to the class of antigrowth hormone. Used in hypothalamic hormone preparations.

Anon. Lanreotide acetate. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 03/11/2020.

Anon. Lanreotide. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 03/11/2020.

Buckingham R (ed). Lanreotide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/11/2020.

Healthcare Logistics. Somatuline Autogel 60, 90 and 120 mg Solution for Injection in a Pre-filled Syringe data sheet 23 June 2020. Medsafe. http://www.medsafe.govt.nz. Accessed 13/11/2020.

Joint Formulary Committee. Lanreotide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/11/2020.

Somatuline Autogel Prolonged-Release Solution for Injection in a Pre-filled Syringe (Ipsen Pharma Biotech). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 13/11/2020.

Somatuline Depot - Lanreotide Acetate Injection (Ipsen Biopharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 13/11/2020.